Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen

被引:41
|
作者
Perez, Luis E.
Chandrasekar, Bysani
Saldarriaga, Omar A.
Zhao, Weiguo
Arteaga, Lourdes T.
Travi, Bruno L.
Melby, Peter C.
机构
[1] Dept Vet Affairs Med Ctr, Res Serv, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA
[2] Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA
[3] Univ Texas, Dept Microbiol & Immunol, Hlth Sci Ctr, San Antonio, TX 78229 USA
[4] Ctr Int Entrenamiento & Invest Med, Cali, Colombia
来源
JOURNAL OF IMMUNOLOGY | 2006年 / 176卷 / 09期
关键词
D O I
10.4049/jimmunol.176.9.5519
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Progressive disease in the hamster model of visceral leishmaniasis, caused by Leishmania donovani, in contrast to infection in mice, mimics the progressive disease observed in untreated humans. During progressive infection in hamsters, there was a vigorous type 1 cellular immune response, which is typically associated with control of infection, suggesting that there was ineffective IFN-gamma-mediated macrophage activation. Indeed, at the site of infection, hamsters did not express NO synthase 2 (NOS2), which is the primary mechanism for control of infection in mice. Furthermore, in striking contrast to mouse macrophages, IFN-gamma-activated hamster macrophages did not did not express NOS2 nor generate NO, and were unable to restrict the replication of intracellular L. donovani. The absent hamster NOS2 expression was not the result of NOS2 gene deletion and the NOS2 cDNA had an intact open reading frame. Furthermore, the impaired transcription of NOS2 mRNA was selective and not due to global impairment of IFN-gamma signaling (members of the IFN-gamma-signaling pathway were expressed and functional and IFN-gamma up-regulated several primary and secondary response genes). Strikingly, the proximal hamster NOS2 promoter, like the human ortholog, had > 20-fold less basal and IFN-gamma/LPS-inducible activity than the corresponding mouse promoter. Thus, reduced basal and IFN-gamma-induced activity of the hamster NOS2 transcriptional unit, which is unique to this small animal and similar to the human counterpart, accompanies the inability of the animal to control an intracellular pathogen.
引用
收藏
页码:5519 / 5528
页数:10
相关论文
共 50 条
  • [1] Nitric oxide synthase 2 (NOS2) promoter polymorphisms in colorectal cancer
    Fransén, K
    Elander, N
    Söderkvist, P
    CANCER LETTERS, 2005, 225 (01) : 99 - 103
  • [2] Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: Initial analysis of the human NOS2 promoter
    deVera, ME
    Shapiro, RA
    Nussler, AK
    Mudgett, JS
    Simmons, RL
    Morris, SM
    Billiar, TR
    Geller, DA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (03) : 1054 - 1059
  • [3] Inducible NO synthase (NOS2) - Cyclooxygenases (COX) interactions in vivo: Implication for pharmacological inhibition of NOS2 activity
    Devaux, Y
    Carole, S
    Paul-Michael, M
    Claude, M
    Dan, L
    ANESTHESIOLOGY, 2000, 93 (3A) : U156 - U156
  • [4] Malaria severity and human nitric oxide synthase type 2 (NOS2) promoter haplotypes
    Marc C. Levesque
    Maurine R. Hobbs
    Charles W. O’Loughlin
    Jennifer A. Chancellor
    Youwei Chen
    Ariana N. Tkachuk
    Jennifer Booth
    Kistie B. Patch
    Sallie Allgood
    Ann R. Pole
    Carolyn A. Fernandez
    Esther D. Mwaikambo
    Theonest K. Mutabingwa
    Michal Fried
    Bess Sorensen
    Patrick E. Duffy
    Donald L. Granger
    Nicholas M. Anstey
    J. Brice Weinberg
    Human Genetics, 2010, 127 : 163 - 182
  • [5] Malaria severity and human nitric oxide synthase type 2 (NOS2) promoter haplotypes
    Levesque, Marc C.
    Hobbs, Maurine R.
    O'Loughlin, Charles W.
    Chancellor, Jennifer A.
    Chen, Youwei
    Tkachuk, Ariana N.
    Booth, Jennifer
    Patch, Kistie B.
    Allgood, Sallie
    Pole, Ann R.
    Fernandez, Carolyn A.
    Mwaikambo, Esther D.
    Mutabingwa, Theonest K.
    Fried, Michal
    Sorensen, Bess
    Duffy, Patrick E.
    Granger, Donald L.
    Anstey, Nicholas M.
    Weinberg, J. Brice
    HUMAN GENETICS, 2010, 127 (02) : 163 - 182
  • [6] Inducible NO synthase (NOS2)-cyclooxygenases (COX) interactions in vivo:: Implication for pharmacological inhibition of NOS2 activity
    Devaux, Y
    Seguin, C
    de Talance, N
    Burlet, C
    Zannad, F
    Meistelman, C
    Longrois, D
    Mertes, PM
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2000, 440 (06): : R231 - R231
  • [7] Inducible nitric oxide synthase (NOS2) is expressed in Achilles tendinopathy
    Riley, G. P.
    Curry, V.
    Hazleman, B. L.
    RHEUMATOLOGY, 2001, 40 : 102 - 102
  • [8] Inducible nitric oxide synthase (NOS2) promoter CCTTT repeat polymorphism:: Relationship to in vivo nitric oxide production/NOS activity in an asymptomatic malaria-endemic population
    Boutlis, CS
    Hobbs, MR
    Marsh, RL
    Misukonis, MA
    Tkachuk, AN
    Lagog, M
    Booth, J
    Granger, DL
    Bockarie, MJ
    Mgone, CS
    Levesque, MC
    Weinberg, JB
    Anstey, NM
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 69 (06): : 569 - 573
  • [9] Inducible nitric oxide synthase (NOS2) knockout mice as a model of trichotillomania
    Casarotto, Plinio C.
    Biojone, Caroline
    Montezuma, Karina
    Cunha, Fernando Q.
    Joca, Samia R. L.
    Castren, Eero
    Guimaraes, Francisco S.
    PEERJ, 2018, 6
  • [10] Inducible nitric oxide synthase (NOS2) gene polymorphism and parasitic diseases
    Martin, J
    Calzada, JE
    Nieto, A
    LANCET, 1999, 353 (9146): : 72 - 72